Rigosertib Combo Fails to Prolong Survival in Higher-risk Myelodysplastic Syndromes
News
When given alongside best supportive care, rigosertib failed to prolong the survival of patients with higher-risk myelodysplastic syndromes (HR-MDS), a group of blood cancers that often progress to acute myeloid ... Read more